CorConsult Rx: Evidence-Based Medicine and Pharmacy

Tirzepatide: A New Frontier for Diabetes Management

02.15.2022 - By Mike Corvino, PharmD, BCPS, BCACP, CDCES and Cole Swanson, PharmD, CDCESPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

On this episode, we review the data for tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes a new medication that is being investigated. We discuss the unique mechanism of action and summarize the data from the SURPASS studies.  Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - [email protected] Cole - [email protected] Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.  

More episodes from CorConsult Rx: Evidence-Based Medicine and Pharmacy